Copyright
©The Author(s) 2017.
World J Hepatol. Jan 18, 2017; 9(2): 80-90
Published online Jan 18, 2017. doi: 10.4254/wjh.v9.i2.80
Published online Jan 18, 2017. doi: 10.4254/wjh.v9.i2.80
Table 1 Randomized Phase III trials in advanced hepatocellular carcinoma
| Drug | n (patients) | OS (mo) | HR |
| SOR/Exp arm | |||
| First line completed (Sorafenib standard) | |||
| Brivanib | 1155 | 9.9/9.5 | 1.06 |
| Sunitinib | 1074 | 10.2/7.9 | 1.3 |
| Sorafenib/Erlotinib | 720 | 8.5/9.5 | 0.92 |
| Linifanib | 1035 | 9.8/9.1 | 1.04 |
| Second line completed (placebo standard) | |||
| Brivanib | 395 | 8.2/9.4 | 0.89 |
| Everolimus | 546 | 7.3/7.6 | 1.05 |
| Ramucirumab | 565 | 7.6/9.2 | 0.86 |
- Citation: Samonakis DN, Kouroumalis EA. Systemic treatment for hepatocellular carcinoma: Still unmet expectations. World J Hepatol 2017; 9(2): 80-90
- URL: https://www.wjgnet.com/1948-5182/full/v9/i2/80.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i2.80